Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection

Background: It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have different effects on hepatocellular carcinoma (HCC) recurrence and death in patients receiving curative hepatectomy for hepatitis B virus (HBV)-related HCC. Aims: The aim of this study was to compare the l...

Full description

Bibliographic Details
Main Authors: Ming-Chao Tsai, Chih-Chi Wang, Wei-Chen Lee, Chih-Che Lin, Kuo-Chin Chang, Chien-Hung Chen, Chao-Hung Hung, Ming-Tsung Lin, Chang-Chun Hsiao, Chao-Long Chen, Rong-Nan Chien, Tsung-Hui Hu
Format: Article
Language:English
Published: Karger Publishers 2021-09-01
Series:Liver Cancer
Subjects:
entecavir
tenofovir disoproxil fumarate
chronic hepatitis b
hepatocellular carcinoma
recurrence
Online Access:https://www.karger.com/Article/FullText/518940

Internet

https://www.karger.com/Article/FullText/518940

Similar Items